Efficacy of Midodrine (drug) in Liver Disease.
Not Applicable
- Conditions
- Health Condition 1: K769- Liver disease, unspecified
- Registration Number
- CTRI/2020/07/026642
- Lead Sponsor
- Institute of Liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
ACLF patients (as per APASL definition) with grade II/III ascites
Exclusion Criteria
1.Age < 18 or >75 years
2.Hepatocellular carcinoma
3.Extrahepatic portal vein obstruction
4.Non cirrhotic ascites
5.Serum creatinine >1.5mg/dl
6.Refractory septic shock
7.Beta blockersPortal vein thrombosis
8.Grade 3â??4 HE
9.Pregnancy or Lactation
10.Active variceal bleed
11.Respiratory, cardiac, renal failure
12.Uncontrolled hypertension
13.Severe coagulopathy
14.Refusal to participate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of PICD at day 3 and day6Timepoint: Day 3 and Day 6
- Secondary Outcome Measures
Name Time Method Changes in hemodynamic parameters at post paracentesisTimepoint: 1, 3 and 6 hour, Day 3, Day 6;Incidence of Hyponatremia, HE and AKI at day 3 and 6Timepoint: Day 3 and day 6;Increase in plasma renin activity at Day 3, Day 6Timepoint: Day 3 and day 6